Exact Mass: 761.3904

Exact Mass Matches: 761.3904

Found 33 metabolites which its exact mass value is equals to given mass value 761.3904, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Lividomycin

LIVIDOMYCIN A SULFATE SALT

C29H55N5O18 (761.3542)


C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic

   

Lividomycin A

LIVIDOMYCIN A SULFATE SALT

C29H55N5O18 (761.3542)


A member of the class of lividomycins that is lividomycin B in which position 4 of the diamino-L-idopyranosyl moiety has been converted into its alpha-D-mannopyranoside. C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic

   

pullularin C

pullularin C

C41H55N5O9 (761.4)


   

5alpha-acetyloxy-8alpha-benzoyloxy-15beta-hydroxy-7beta-isobutanoyloxy-9alpha-nicotinyloxy-3beta-propanoyloxyjatropha-6(17),11E-diene-14-one|euphodendrophane H

5alpha-acetyloxy-8alpha-benzoyloxy-15beta-hydroxy-7beta-isobutanoyloxy-9alpha-nicotinyloxy-3beta-propanoyloxyjatropha-6(17),11E-diene-14-one|euphodendrophane H

C42H51NO12 (761.3411)


   
   

SHexCer 14:2;2O/18:2;O

SHexCer 14:2;2O/18:2;O

C38H67NO12S (761.4384)


   

SHexCer 18:3;2O/14:1;O

SHexCer 18:3;2O/14:1;O

C38H67NO12S (761.4384)


   

SHexCer 14:3;2O/18:1;O

SHexCer 14:3;2O/18:1;O

C38H67NO12S (761.4384)


   

SHexCer 16:2;2O/16:2;O

SHexCer 16:2;2O/16:2;O

C38H67NO12S (761.4384)


   

SHexCer 20:3;2O/12:1;O

SHexCer 20:3;2O/12:1;O

C38H67NO12S (761.4384)


   

SHexCer 19:3;2O/13:1;O

SHexCer 19:3;2O/13:1;O

C38H67NO12S (761.4384)


   

SHexCer 17:3;2O/15:1;O

SHexCer 17:3;2O/15:1;O

C38H67NO12S (761.4384)


   

SHexCer 16:3;2O/16:1;O

SHexCer 16:3;2O/16:1;O

C38H67NO12S (761.4384)


   
   

(2S)-2-amino-3-[[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C41H64NO10P (761.4268)


   

(2S)-2-amino-3-[[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C41H64NO10P (761.4268)


   

(2S)-2-amino-3-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(10E,13E,16E)-nonadeca-10,13,16-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(10E,13E,16E)-nonadeca-10,13,16-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C41H64NO10P (761.4268)


   
   
   
   
   
   
   
   
   
   

TFLLR-NH2(TFA)

TFLLR-NH2(TFA)

C33H54F3N9O8 (761.4047)


TFLLR-NH2 (TFA) is a selective PAR1 agonist with an EC50 of 1.9 μM.

   

(3s,6s,12s,15s,18s,23as)-6,12-bis[(2s)-butan-2-yl]-1,4,7,10,13,16-hexahydroxy-18-(3h-imidazol-4-ylmethyl)-3-(2-methylpropyl)-15-[2-(methylsulfanyl)ethyl]-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-19-one

(3s,6s,12s,15s,18s,23as)-6,12-bis[(2s)-butan-2-yl]-1,4,7,10,13,16-hexahydroxy-18-(3h-imidazol-4-ylmethyl)-3-(2-methylpropyl)-15-[2-(methylsulfanyl)ethyl]-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-19-one

C36H59N9O7S (761.4258)


   

2-{[5-amino-2-(aminomethyl)-6-({5-[(3,5-diamino-2-{[3-amino-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl)oxy]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl}oxy)-4-hydroxyoxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

2-{[5-amino-2-(aminomethyl)-6-({5-[(3,5-diamino-2-{[3-amino-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl)oxy]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl}oxy)-4-hydroxyoxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C29H55N5O18 (761.3542)


   

15-benzyl-1,7-dihydroxy-3-(hydroxymethyl)-6-isopropyl-5,11,12-trimethyl-9-({4-[(3-methylbut-2-en-1-yl)oxy]phenyl}methyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclooctadecane-4,10,13,16-tetrone

15-benzyl-1,7-dihydroxy-3-(hydroxymethyl)-6-isopropyl-5,11,12-trimethyl-9-({4-[(3-methylbut-2-en-1-yl)oxy]phenyl}methyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclooctadecane-4,10,13,16-tetrone

C41H55N5O9 (761.4)


   

2-({2-[(2-{2-[(3-amino-10-chloro-1,2-dihydroxydecylidene)amino]-n-methylpropanamido}-1-hydroxy-4-methylpentylidene)amino]-1-hydroxy-3-(4-hydroxyphenyl)propylidene}amino)-3-(4-hydroxyphenyl)propanoic acid

2-({2-[(2-{2-[(3-amino-10-chloro-1,2-dihydroxydecylidene)amino]-n-methylpropanamido}-1-hydroxy-4-methylpentylidene)amino]-1-hydroxy-3-(4-hydroxyphenyl)propylidene}amino)-3-(4-hydroxyphenyl)propanoic acid

C38H56ClN5O9 (761.3766)


   

(3s,6s,9s,12s,15r,20as)-15-benzyl-1,7-dihydroxy-3-(hydroxymethyl)-6-isopropyl-5,11,12-trimethyl-9-({4-[(3-methylbut-2-en-1-yl)oxy]phenyl}methyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclooctadecane-4,10,13,16-tetrone

(3s,6s,9s,12s,15r,20as)-15-benzyl-1,7-dihydroxy-3-(hydroxymethyl)-6-isopropyl-5,11,12-trimethyl-9-({4-[(3-methylbut-2-en-1-yl)oxy]phenyl}methyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclooctadecane-4,10,13,16-tetrone

C41H55N5O9 (761.4)